EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Treating Adenovirus Infection in Transplant Populations: Therapeutic Options Beyond Cidofovir?

Niyati Narsana, David Ha, Dora Y Ho

Viruses · 2025

DOI: 10.3390/v17050599 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Niyati Narsana und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, UC Davis Medical Center, Sacramento, CA 95817, USA. Hauptthemen laut MEDLINE: Antiviral Agents, Cidofovir, Adenoviridae Infections, Transplant Recipients. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adenovirus (AdV) infections can lead to significant morbidity and increased mortality in immunocompromised populations such as hematopoietic stem cell and solid organ transplant recipients. This review evaluates currently available and emerging therapies for AdV infections. Cidofovir, while most commonly used, is limited by its variable efficacy and nephrotoxicity. This led to the development of brincidofovir, which has a better safety profile and great in vitro potency against AdV. The use of ribavirin and ganciclovir has been reported in the literature, but their use is limited due to inconsistent efficacy. Immune-based approaches, such as adoptive T-cell therapy, have shown promise in achieving viral clearance and improving survival but remain constrained by challenges related to manufacturing complexity and risks of graft-versus-host disease. This review underscores the need for standardized treatment protocols as well as comparative studies to identify optimal dosing and timing to initiate treatment. Future research should focus on individualized treatment approaches and the development of novel therapeutic agents to address the unmet clinical needs of AdV management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCidofovirAdenoviridae InfectionsTransplant RecipientsAdenovirus Infections, HumanHumansCytosineImmunocompromised HostOrganophosphonates

Stichwörter der Autor:innen

adenovirusadoptive T-cell therapybrincidofovircidofovirganciclovirhematopoietic stem cell transplantribavirinsolid organ transplant

Substanzen

Antiviral AgentsCidofovirCytosinebrincidofovirOrganophosphonates

Autor:innen und Institutionen

  • Division of Infectious Diseases, UC Davis Medical Center, Sacramento, CA 95817, USA.
  • Stanford Antimicrobial Safety and Sustainability Program, Stanford Health Care, Stanford, CA 94305, USA.
  • Division of Infectious Diseases & Geographic Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.

Zitieren

APA

Narsana, N., Ha, D., & Ho, D. Y. (2025). Treating Adenovirus Infection in Transplant Populations: Therapeutic Options Beyond Cidofovir?. Viruses. https://doi.org/10.3390/v17050599

Vancouver

Narsana N, Ha D, Ho DY. Treating Adenovirus Infection in Transplant Populations: Therapeutic Options Beyond Cidofovir?. Viruses. 2025. doi:10.3390/v17050599

BibTeX
@article{Narsana2025,
  author = {Narsana, Niyati and Ha, David and Ho, Dora Y},
  title = {Treating Adenovirus Infection in Transplant Populations: Therapeutic Options Beyond Cidofovir?},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17050599}
}
Kostenlos starten →